| Domain | Evidence-backed finding | Knowledge-base annotation/caveat |
|---|---|---|
| Disease entity | **Hennekam lymphangiectasia-lymphedema syndrome 2** is a Mendelian syndromic primary lymphatic disorder; Open Targets maps it to **MONDO:0014454** and links the disease specifically to **FAT4** (pqac-00000000) | Disease-level resource plus primary literature; subtype-specific entry should be kept separate from CCBE1-related Hennekam syndrome 1 and ADAMTS3-related syndrome 3 (pqac-00000016, pqac-00000015) |
| Causal gene | Causal gene is **FAT4** (**FAT atypical cadherin 4**), a large atypical cadherin involved in planar cell polarity and development (pqac-00000018, pqac-00000000) | Use HGNC gene symbol **FAT4**; disease mechanism is consistent with impaired FAT4 function rather than a gain-of-function state (inference from recessive human disease and knockout/model data) (pqac-00000019, pqac-00000006) |
| Inheritance / variant class | Reported subtype 2 cases show **autosomal recessive**, **biallelic germline** FAT4 variants; example HS patient had homozygous **c.5297A>G (p.Asp1766Gly)**; prior reports include other homozygous/compound heterozygous damaging variants in FAT4-associated allelic disorders (pqac-00000014, pqac-00000016) | Variant interpretation should follow ACMG/AMP; currently available evidence supports damaging/likely loss-of-function biology, but subtype-specific variant spectrum remains sparse because the condition is ultrarare (pqac-00000014, pqac-00000015) |
| Defining phenotype | Core phenotype is **lymphatic dysplasia** with **lymphedema** and **lymphangiectasia**, often with facial anomalies and variable developmental/intellectual effects; original syndrome description and later series emphasize edema of face/limbs/genitalia and intestinal lymphangiectasia (pqac-00000016, pqac-00000005) | Useful HPO terms: **Lymphedema (HP:0001004)**, **Intestinal lymphangiectasia**, **Generalized edema**, **Hypertelorism (HP:0000316)**, **Epicanthus (HP:0000286)**, **Developmental delay (HP:0001263)** / **Intellectual disability (HP:0001249)**; subtype 2 evidence is still based on very few FAT4-confirmed patients (pqac-00000014, pqac-00000015) |
| FAT4 subtype clinical details | In the FAT4-confirmed HS case, features included respiratory distress at birth, generalized edema starting at **8 months**, recurrent respiratory/intestional infections, abdominal distension, umbilical hernia, periorbital edema, conical teeth, gingival hypertrophy, and normal-to-mildly affected cognition after speech delay (pqac-00000014, pqac-00000004) | This is strong patient-level evidence but mainly from isolated cases; do not overstate frequency estimates for FAT4 subtype 2 specifically (pqac-00000004) |
| Age of onset / natural history | Comparative review indicates **CCBE1-related HS often has lymphedema at birth**, whereas **FAT4-related HS can present later in childhood** (pqac-00000015) | This is one of the clearest subtype-distinguishing features currently available; still based on limited published cohorts (pqac-00000015) |
| Laboratory / GI manifestations | FAT4-HS can include **hypoalbuminemia**, **hypoproteinemia**, **hypogammaglobulinemia**, elevated IgE/eosinophilia, abdominal distension, and endoscopic evidence suggestive of intestinal lymphatic disease/protein loss (pqac-00000014, pqac-00000004) | Knowledge-base should distinguish direct findings (serum albumin/protein abnormalities) from histology, which may be nondiagnostic in some biopsies despite clinical suspicion (pqac-00000014) |
| Mechanism | FAT4 and **DCHS1** form a **heterophilic cadherin** receptor-ligand pair that regulates **planar cell polarity (PCP)**; in lymphatics this signaling controls **valve endothelial cell polarization** and **lymphatic valve morphogenesis** (pqac-00000019, pqac-00000006, pqac-00000007) | Useful GO/CL terms: **planar cell polarity**, **cell-cell adhesion**, **lymph vessel development**, **valve morphogenesis**; cell type: **lymphatic endothelial cell** / **valve endothelial cell**. Disease mechanism is supported directly by model systems and plausibly explains human lymphedema (pqac-00000007, pqac-00000008) |
| Mechanistic chain | Mouse data show overall lymphatic vessel architecture can be present, but valve formation is defective: mutant valve endothelial cells are disoriented and fail to form proper leaflets; ~**60% of valves were abnormal** in Fat4/Dchs1 mutants, with reduced proper orientation versus controls (pqac-00000019, pqac-00000007) | Upstream: FAT4-DCHS1 adhesion/polarity signaling. Downstream: impaired endothelial polarization, migration, and valve leaflet formation, leading to dysfunctional lymph drainage and lymphedema (pqac-00000007, pqac-00000008) |
| 2023-2024 research update | A 2023 structural study solved human **FAT4–DCHS1** binding-domain structures and showed the interface spans **EC1-4** of each protein with high-affinity binding; this refines the molecular basis of subtype 2 pathogenesis (pqac-00000018, pqac-00000010) | Recent mechanistic advance is structural rather than clinical; no 2023-2024 large natural-history cohort specific to FAT4-HS was identified in the retrieved evidence (pqac-00000018) |
| Diagnostics | Diagnostic approach is **clinical recognition of syndromic primary lymphedema** plus confirmation of lymphatic dysfunction (e.g., **lymphoscintigraphy**) and **molecular confirmation** of biallelic FAT4 variants using **lymphedema gene panel**, **WES**, or **WGS** (pqac-00000017, pqac-00000014) | Lymphoscintigraphy is useful to confirm lymphedema generally; targeted single-gene testing may miss atypical cases, so panel/exome/genome approaches are reasonable when phenotype is syndromic (pqac-00000017, pqac-00000014) |
| Differential diagnosis | Must be distinguished from other syndromic primary lymphedemas and from **Van Maldergem syndrome**; VMS shares facial gestalt/intellectual issues but has neonatal hypotonia, feeding/breathing problems, hearing loss, tracheal anomalies, and osteopenia rather than prominent lymphatic anomalies (pqac-00000016, pqac-00000015) | Also clinically exclude non-lymphatic causes of swelling such as **lipedema** and secondary lymphedema causes; these recommendations are extrapolated from primary lymphedema guidelines (pqac-00000017) |
| Management | No curative therapy is established; supportive care includes **complete decongestive therapy**, **compression bandaging/garments**, **manual lymph drainage**, **exercise**, skin care/hygiene, limb elevation, and education; intestinal lymphangiectasia/protein-losing enteropathy may benefit from **high-protein, low-fat / medium-chain triglyceride nutrition** and albumin support (pqac-00000013, pqac-00000012, pqac-00000017) | NCIT-style intervention concepts: compression therapy, physical therapy, nutritional support. Most treatment evidence is syndrome-general or case-based rather than FAT4-subtype trials (pqac-00000012, pqac-00000013) |
| Outcomes / QoL | Primary lymphedema can have major **functional and psychological** effects on quality of life, and cellulitis is a key complication; case evidence suggests edema reduction is achievable with conservative therapy (pqac-00000017, pqac-00000013) | No robust FAT4-specific survival or QoL cohort was identified; prognosis is therefore inferred from syndrome severity, organ involvement, and control of edema/protein loss (pqac-00000017) |
| Disease-modifying therapy / trials | **No approved disease-modifying therapy** or subtype-specific targeted therapy was identified; no relevant interventional trial specific to Hennekam syndrome was retrieved (pqac-00000013, pqac-00000017) | Important negative finding for knowledge base: management is supportive; research remains preclinical/mechanistic rather than therapeutic (pqac-00000006, pqac-00000018) |
| Evidence limitations | Condition is **ultrarare**; by 2018 only **40 HS patients** overall had been reported, with molecular heterogeneity across **CCBE1, FAT4, and ADAMTS3**, and only sparse FAT4-confirmed subtype 2 cases (pqac-00000016, pqac-00000015) | Frequency estimates, penetrance, genotype-phenotype correlation, prevalence, and many prognosis fields should be marked **not well established / insufficient subtype-specific data** (pqac-00000015) |


*Table: This compact table summarizes the most actionable disease-characteristic facts for FAT4-related Hennekam lymphangiectasia-lymphedema syndrome 2. It is designed for rapid population of a knowledge-base entry while clearly marking where evidence is subtype-specific versus extrapolated.*